Optimer Pharmaceuticals (OPTR) Posts Q2 Profit of $0.02/Sh

February 28, 2013 4:29 PM EST
Get Alerts OPTR Hot Sheet
Trade OPTR Now!
Join SI Premium – FREE
Optimer Pharmaceuticals (NASDAQ: OPTR) reported Q4 EPS of $0.02, which may not compare to the estimate of ($0.38). Revenue for the quarter came in at $19.5 million versus the consensus estimate of $18.05 million.

"2012 was an exciting year for Optimer. DIFICID is now available in over a dozen countries," said Dr. Henry McKinnell, Optimer's CEO and Chairman of the Board. "In the U.S. we will be focusing on improving the formulary status of DIFICID in the hospital marketplace and on expanding the use of this important new medicine in all channels."

For earnings history and earnings-related data on Optimer Pharmaceuticals (OPTR) click here.

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In

Related Categories


Related Entities


Add Your Comment